

Jan KrÄjnke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4621240/publications.pdf>

Version: 2024-02-01

45
papers

5,107
citations

279701

23
h-index

254106

43
g-index

45
all docs

45
docs citations

45
times ranked

7311
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells. <i>Science</i> , 2014, 343, 301-305.	6.0	1,371
2	<i>IDH1</i> and <i>IDH2</i> Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With <i>NPM1</i> Mutation Without <i>FLT3</i> Internal Tandem Duplication. <i>Journal of Clinical Oncology</i> , 2010, 28, 3636-3643.	0.8	728
3	Lenalidomide induces ubiquitination and degradation of CK1 α in <i>del(5q)</i> MDS. <i>Nature</i> , 2015, 523, 183-188.	13.7	648
4	Monitoring of Minimal Residual Disease in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 2709-2716.	0.8	355
5	Clonal evolution in relapsed <i>NPM1</i> -mutated acute myeloid leukemia. <i>Blood</i> , 2013, 122, 100-108.	0.6	242
6	Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 775-783.	0.8	222
7	Alternative Approaches for Efficient Inhibition of Hepatitis C Virus RNA Replication by Small Interfering RNAs. <i>Journal of Virology</i> , 2004, 78, 3436-3446.	1.5	158
8	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. <i>Blood</i> , 2012, 120, e83-e92.	0.6	131
9	Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. <i>Leukemia</i> , 2010, 24, 438-449.	3.3	125
10	Homo-PROTACs for the Chemical Knockdown of Cereblon. <i>ACS Chemical Biology</i> , 2018, 13, 2771-2782.	1.6	114
11	Clonal evolution patterns in acute myeloid leukemia with <i>NPM1</i> mutation. <i>Nature Communications</i> , 2019, 10, 2031.	5.8	87
12	Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. <i>Chemical Science</i> , 2020, 11, 3474-3486.	3.7	77
13	PROTAC-mediated crosstalk between E3 ligases. <i>Chemical Communications</i> , 2019, 55, 1821-1824.	2.2	74
14	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i> -mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020, 136, 3041-3050.	0.6	73
15	Circular RNAs of the nucleophosmin (<i>NPM1</i>) gene in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 2039-2047.	1.7	72
16	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012, 119, e67-e75.	0.6	66
17	Lenalidomide induces degradation of IKZF1 and IKZF3. <i>OncImmunology</i> , 2014, 3, e941742.	2.1	63
18	DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 30-37.	3.3	50

#	ARTICLE	IF	CITATIONS
19	A MedChem toolbox for cereblon-directed PROTACs. <i>MedChemComm</i> , 2019, 10, 1037-1041.	3.5	44
20	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). <i>Journal of Clinical Oncology</i> , 2021, 39, 3318-3327.	0.8	44
21	Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. <i>Leukemia</i> , 2020, 34, 1182-1186.	3.3	39
22	IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). <i>Leukemia</i> , 2017, 31, 1363-1367.	3.3	38
23	The molecular mechanism of thalidomide analogs in hematologic malignancies. <i>Journal of Molecular Medicine</i> , 2016, 94, 1327-1334.	1.7	36
24	Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. <i>Nature Communications</i> , 2022, 13, 1009.	5.8	28
25	The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages. <i>Cancer Immunology Research</i> , 2021, 9, 265-278.	1.6	26
26	Cereblon enhancer methylation and IMiD resistance in multiple myeloma. <i>Blood</i> , 2021, 138, 1721-1726.	0.6	25
27	Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1733-1738.	1.3	25
28	Community-driven development of a modified progression-free survival ratio for precision oncology. <i>ESMO Open</i> , 2019, 4, e000583.	2.0	22
29	Lenalidomide Induces Ubiquitination and Degradation of CSNK1A1 in MDS with Del(5q). <i>Blood</i> , 2014, 124, 4-4.	0.6	19
30	Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. <i>Leukemia</i> , 2015, 29, 1942-1945.	3.3	18
31	Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). <i>Leukemia</i> , 2020, 34, 404-415.	3.3	16
32	Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy. <i>Cancers</i> , 2020, 12, 3764.	1.7	13
33	Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. <i>Haematologica</i> , 2014, 99, e133-e135.	1.7	11
34	Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	10
35	Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2391-2402.	2.5	10
36	MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses. <i>Haematologica</i> , 2016, 101, e454-e456.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2018, 379, 1873-1874.	13.9	6
38	Comment on "Integrative genomic profiling of human prostate cancer". <i>Leukemia</i> , 2010, 24, 1970-1972.	3.3	4
39	Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma. <i>Oncotarget</i> , 2017, 8, 106163-106164.	0.8	4
40	Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. <i>American Journal of Hematology</i> , 2021, 96, E207-E210.	2.0	2
41	Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn. <i>Experimental Hematology</i> , 2021, 93, 61-69.e4.	0.2	1
42	Triggering T-cell activity in CLL. <i>Blood</i> , 2021, 137, 150-151.	0.6	1
43	Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT). <i>Blood</i> , 2018, 132, 1979-1979.	0.6	1
44	Lenalidomide Promotes CRBN-Mediated Ubiquitination and Degradation of IKZF1 and IKZF3. <i>Blood</i> , 2013, 122, LBA-5-LBA-5.	0.6	1
45	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. <i>Blood</i> , 2013, 122, 2555-2555.	0.6	0